New endometriosis and diabetes treatments earn PBAC approval
The committee also recommended romosozumab (Evenity) be subsidised for severe osteoporosis in first-line settings.
A new endometriosis treatment has been given the PBS green light just three months after it was approved by the TGA.
The once-daily combination pill Ryeqo, which contains the gonadotropin-releasing hormone antagonist relugolix 40mg, oestradiol 1mg and norethisterone 0.5mg, was initially indicated for uterine fibroids.
Following its March meeting, the PBAC recommended an authority required (streamlined) listing for Ryeqo for treating moderate and severe endometriosis-related pain.
This expanded indication was approved by the TGA in late January, allowing doctors to prescribe the combined preparation for women who have tried other medications or undergone surgery for endometriosis.
